Literature DB >> 24101374

64Cu- and 68Ga-labelled [Nle(14),Lys(40)(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta cell imaging in rats.

Kirsi Mikkola, Mikkola Kirsi1, Cheng-Bin Yim, Yim Cheng-Bin, Veronica Fagerholm, Fagerholm Veronica, Tamiko Ishizu, Ishizu Tamiko, Viki-Veikko Elomaa, Elomaa Viki-Veikko, Johan Rajander, Rajander Johan, Jori Jurttila, Jurttila Jori, Tiina Saanijoki, Saanijoki Tiina, Tuula Tolvanen, Tolvanen Tuula, Marko Tirri, Tirri Marko, Eleni Gourni, Gourni Eleni, Martin Béhé, Béhé Martin, Martin Gotthardt, Gotthardt Martin, Jean Claude Reubi, Reubi Jean Claude, Helmut Mäcke, Mäcke Helmut, Anne Roivainen, Roivainen Anne, Olof Solin, Solin Olof, Pirjo Nuutila, Nuutila Pirjo.   

Abstract

PURPOSE: Glucagon-like peptide-1 receptor (GLP-1R) is a molecular target for imaging of pancreatic beta cells. We compared the ability of [Nle(14),Lys(40)(Ahx-NODAGA-(64)Cu)NH2]-exendin-4 ([(64)Cu]NODAGA-exendin-4) and [Nle(14),Lys(40)(Ahx-NODAGA-(68)Ga)NH2]-exendin-4 ([(68)Ga]NODAGA-exendin-4) to detect native pancreatic islets in rodents. PROCEDURES: The stability, lipophilicity and affinity of the radiotracers to the GLP-1R were determined in vitro. The biodistribution of the tracers was assessed using autoradiography, ex vivo biodistribution and PET imaging. Estimates for human radiation dosimetry were calculated.
RESULTS: We found GLP-1R-specific labelling of pancreatic islets. However, the pancreas could not be visualised in PET images. The highest uptake of the tracers was observed in the kidneys. Effective dose estimates for [(64)Cu]NODAGA-exendin-4 and [(68)Ga]NODAGA-exendin-4 were 0.144 and 0.012 mSv/MBq, respectively.
CONCLUSION: [(64)Cu]NODAGA-exendin-4 might be more effective for labelling islets than [(68)Ga]NODAGA-exendin-4. This is probably due to the lower specific radioactivity of [(68)Ga]NODAGA-exendin-4 compared to [(64)Cu]NODAGA-exendin-4. The radiation dose in the kidneys may limit the use of [(64)Cu]NODAGA-exendin-4 as a clinical tracer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24101374     DOI: 10.1007/s11307-013-0691-2

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  33 in total

Review 1.  Gut hormones as pharmaceuticals. From enteroglucagon to GLP-1 and GLP-2.

Authors:  J J Holst
Journal:  Regul Pept       Date:  2000-09-25

2.  A new technique for in vivo imaging of specific GLP-1 binding sites: first results in small rodents.

Authors:  Martin Gotthardt; Georg Lalyko; Julliëtte van Eerd-Vismale; Boris Keil; Tino Schurrat; Michael Hower; Peter Laverman; Thomas M Behr; Otto C Boerman; Burkhard Göke; Martin Béhé
Journal:  Regul Pept       Date:  2006-08-22

Review 3.  Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting.

Authors:  Jean Claude Reubi; Beatrice Waser
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-18       Impact factor: 9.236

4.  Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas.

Authors:  Damian Wild; Emanuel Christ; Martyn E Caplin; Tom R Kurzawinski; Flavio Forrer; Michael Brändle; Jochen Seufert; Wolfgang A Weber; Jamshed Bomanji; Aurel Perren; Peter J Ell; Jean Claude Reubi
Journal:  J Nucl Med       Date:  2011-06-16       Impact factor: 10.057

5.  GLP-1-(7-36) amide, -(1-37), and -(1-36) amide: potent cAMP-dependent stimuli of rat parietal cell function.

Authors:  J Schmidtler; W Schepp; I Janczewska; N Weigert; C Fürlinger; V Schusdziarra; M Classen
Journal:  Am J Physiol       Date:  1991-06

Review 6.  Radionuclide probes for molecular imaging of pancreatic beta-cells.

Authors:  Zhanhong Wu; Fouad Kandeel
Journal:  Adv Drug Deliv Rev       Date:  2010-09-18       Impact factor: 15.470

7.  GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting.

Authors:  Meike Körner; Martin Stöckli; Beatrice Waser; Jean Claude Reubi
Journal:  J Nucl Med       Date:  2007-05       Impact factor: 10.057

8.  MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.

Authors:  Barry W Wessels; Mark W Konijnenberg; Roger G Dale; Hazel B Breitz; Marta Cremonesi; Ruby F Meredith; Alan J Green; Lionel G Bouchet; A Bertrand Brill; Wesley E Bolch; George Sgouros; Stephen R Thomas
Journal:  J Nucl Med       Date:  2008-10-16       Impact factor: 10.057

9.  Expression of the GLP-1 receptor in mouse, rat, and human pancreas.

Authors:  Ditte Tornehave; Peter Kristensen; John Rømer; Lotte Bjerre Knudsen; R Scott Heller
Journal:  J Histochem Cytochem       Date:  2008-06-09       Impact factor: 2.479

10.  Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice.

Authors:  Erik Vegt; Marleen Melis; Annemarie Eek; Monique de Visser; Maarten Brom; Wim J G Oyen; Martin Gotthardt; Marion de Jong; Otto C Boerman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-18       Impact factor: 9.236

View more
  33 in total

Review 1.  Molecular imaging of β-cells: diabetes and beyond.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quan-Yong Luo; Weibo Cai
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

2.  Dosimetry of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 in rodents, pigs, non-human primates and human - repeated scanning in human is possible.

Authors:  Ram Kumar Selvaraju; Thomas N Bulenga; Daniel Espes; Mark Lubberink; Jens Sörensen; Barbro Eriksson; Sergio Estrada; Irina Velikyan; Olof Eriksson
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-02-15

3.  A standardized method for in vivo mouse pancreas imaging and semiquantitative β cell mass measurement by dual isotope SPECT.

Authors:  Iris Mathijs; Catarina Xavier; Cindy Peleman; Vicky Caveliers; Maarten Brom; Martin Gotthardt; Pedro L Herrera; Tony Lahoutte; Luc Bouwens
Journal:  Mol Imaging Biol       Date:  2015-02       Impact factor: 3.488

Review 4.  In vivo imaging of beta cells with radiotracers: state of the art, prospects and recommendations for development and use.

Authors:  Olof Eriksson; Maren Laughlin; Maarten Brom; Pirjo Nuutila; Michael Roden; Albert Hwa; Riccardo Bonadonna; Martin Gotthardt
Journal:  Diabetologia       Date:  2016-04-19       Impact factor: 10.122

5.  Dual-purpose linker for alpha helix stabilization and imaging agent conjugation to glucagon-like peptide-1 receptor ligands.

Authors:  Liang Zhang; Tejas Navaratna; Jianshan Liao; Greg M Thurber
Journal:  Bioconjug Chem       Date:  2015-01-28       Impact factor: 4.774

6.  Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging.

Authors:  Nilantha Bandara; Alex Zheleznyak; Kaavya Cherukuri; David A Griffith; Chris Limberakis; David A Tess; Chen Jianqing; Rikki Waterhouse; Suzanne E Lapi
Journal:  Mol Imaging Biol       Date:  2016-02       Impact factor: 3.488

7.  Quantitative Impact of Plasma Clearance and Down-regulation on GLP-1 Receptor Molecular Imaging.

Authors:  Liang Zhang; Greg M Thurber
Journal:  Mol Imaging Biol       Date:  2016-02       Impact factor: 3.488

8.  A Synthetic Heterobivalent Ligand Composed of Glucagon-Like Peptide 1 and Yohimbine Specifically Targets β Cells Within the Pancreas.

Authors:  Leah V Steyn; Kameswari Ananthakrishnan; Miranda J Anderson; Renata Patek; Amy Kelly; Josef Vagner; Ronald M Lynch; Sean W Limesand
Journal:  Mol Imaging Biol       Date:  2015-01-21       Impact factor: 3.488

9.  Fully automated GMP production of [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 for clinical use.

Authors:  Irina Velikyan; Ulrika Rosenstrom; Olof Eriksson
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-07-15

10.  Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.

Authors:  Yaping Luo; Qingqing Pan; Shaobo Yao; Miao Yu; Wenming Wu; Huadan Xue; Dale O Kiesewetter; Zhaohui Zhu; Fang Li; Yupei Zhao; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2016-01-21       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.